ENXTPA:BSD
ENXTPA:BSDCapital Markets

Undiscovered Gems in Europe to Watch This January 2026

As we enter January 2026, the European market is showing robust momentum, with the STOXX Europe 600 Index reaching new highs and closing out 2025 with an impressive annual price return. This positive economic backdrop provides a fertile ground for small-cap companies to thrive, making it an opportune moment to explore lesser-known stocks that could potentially benefit from these favorable conditions.
ENXTPA:ML
ENXTPA:MLAuto Components

European Dividend Stocks To Consider In January 2026

As the European markets continue to show strength, with the STOXX Europe 600 Index reaching new highs and closing out 2025 with a robust annual return, investors are increasingly turning their attention to dividend stocks as a means of capitalizing on this positive economic backdrop. In such an environment, selecting dividend stocks that not only offer attractive yields but also demonstrate stability and growth potential can be an effective strategy for income-focused investors looking to...
ENXTPA:ARG
ENXTPA:ARGIndustrial REITs

Argan (ENXTPA:ARG) Valuation Check After Higher Rental Income And Planned 2026 Investments

Argan (ENXTPA:ARG) has reported 2025 rental income of €212.0 million, a 7% increase from 2024, with its warehouse portfolio appraised at €4.1b and around €165 million of investments already lined up for 2026. See our latest analysis for Argan. At a share price of €66.0, Argan’s recent 1 month share price return of 3.94% and 1 year total shareholder return of 13.97% suggest momentum has picked up after more muted multi year total shareholder returns. If Argan’s warehouse income story has your...
ENXTPA:HO
ENXTPA:HOAerospace & Defense

Thales (ENXTPA:HO) Valuation Check After Recent Share Price Momentum Rebuild

With no single headline event driving attention today, Thales (ENXTPA:HO) is back on investors’ radars after a recent share price move. This has prompted closer scrutiny of its valuation and recent performance trends. See our latest analysis for Thales. The recent 7 day share price return of 7.9% and 1 month share price return of 10.6% suggest momentum is rebuilding, set against a 90 day share price decline of 6.4% and a much stronger 1 year total shareholder return of 80.5%. If this move in...
ENXTPA:TKO
ENXTPA:TKOCapital Markets

Tikehau Capital (ENXTPA:TKO) Valuation Check After Recent Share Price Gains

Tikehau Capital (ENXTPA:TKO) has drawn attention after recent share price gains over the past month, alongside reported revenue of €611.739m and net income of €184.725m, putting its last close of €16.64 under closer investor scrutiny. See our latest analysis for Tikehau Capital. The recent 11.08% 1 month share price return, following a weaker 10.25% 3 month share price return and a 16.68% 1 year total shareholder return decline, indicates short term momentum emerging against a softer longer...
ENXTPA:TTE
ENXTPA:TTEOil and Gas

Is It Time To Reassess TotalEnergies (ENXTPA:TTE) After Recent Share Price Weakness?

If you are wondering whether TotalEnergies is attractively priced right now, the key question is whether the current share price reflects its underlying cash generation and asset base. The stock last closed at €55.04, with a 7 day return of 2.4% decline, a 30 day return of 2.4% decline, year to date return of 1.9% decline, and a 1 year return of 6.4%, while the 3 year return sits at 10.9% and the 5 year return at 100.5%. Recent price moves have come alongside ongoing attention on large...
ENXTPA:EL
ENXTPA:ELMedical Equipment

Is LensCrafters’ Omnichannel Optometry Push Reframing EssilorLuxottica’s (ENXTPA:EL) Brand-led Competitive Edge?

LensCrafters, part of EssilorLuxottica, recently continued its Dedicated to Everyday Excellence 360-degree omnichannel campaign, featuring immersive in-store and digital experiences and spotlighting Independent Optometrist Dr. Anisha Haji’s commitment to patient care and leadership in optometry. This renewed campaign underlines EssilorLuxottica’s focus on professional expertise and consumer trust as differentiators in the competitive optical retail and eye-care market. Now we’ll examine how...
ENXTPA:SAN
ENXTPA:SANPharmaceuticals

The Bull Case For Sanofi (ENXTPA:SAN) Could Change Following FDA Priority Review Of Tzield Expansion

In recent days, the US FDA accepted a priority review of Sanofi’s supplemental application for Tzield, aiming to extend its use to children aged one year and older with stage 2 type 1 diabetes, supported by interim PETITE-T1D Phase 4 data and a target decision date of April 29, 2026. This accelerated review could meaningfully broaden Tzield’s eligible pediatric population, underscoring Sanofi’s efforts to address early-stage autoimmune disease in very young patients. We’ll now examine how...